A Study of TAS-120 in Patients With Advanced Solid Tumors



Status:Recruiting
Conditions:Prostate Cancer, Liver Cancer, Cancer, Brain Cancer, Blood Cancer, Women's Studies, Hematology, Hematology
Therapuetic Areas:Hematology, Oncology, Reproductive
Healthy:No
Age Range:18 - Any
Updated:12/21/2018
Start Date:July 2014
End Date:September 2019
Contact:Jerry Huang, MD
Email:jhuang@taihooncology.com

Use our guide to learn which trials are right for you!

Phase 1/2 Study of TAS-120 in Patients With Advanced Solid Tumors Harboring FGF/FGFR Aberrations

This is an open-label, nonrandomized, Phase 1 dose-escalation, dose-expansion, and Phase 2
study targeting tumors with FGF/FGFR aberrations. The purpose of the study is to evaluate the
safety, tolerability, PK, pharmacodynamic, and anti-tumor activity of TAS-120 in patients
with advanced solid tumors with and without FGF/FGFR-related abnormalities.

The study will be conducted in 3 parts, (1) Dose escalation to determine the MTD and/ or RP2D
of TAS-120 in which this part of the study has been completed; (2) Phase 1 expansion to
further evaluate the safety and efficacy of RP2D of TAS-120 in patients with tumors harboring
specific FGFR aberrations, specifically in patients with cholangiocarcinoma, gliomas ,
urothelial carcinomas and any other tumors with FGFR fusion or activating mutation or
amplification. Up to approximately 185 patients will be enrolled in the phase 1 expansion;
and (3) Phase 2 study to confirm ORR of TAS-120 in intra-hepatic CCA patients with tumors
harboring FGFR2 gene fusions. Approx. 100 patients will be enrolled in phase 2.

Phase 1 Dose Escalation Phase 1 Dose Escalation has been completed as of Dec 2017

Phase 1 Dose Expansion:

Up to approximately 185 patients will be enrolled among the 8 groups as outlined below:

- Group 1- CCA (iCCA or eCCA) with FGFR2 gene fusions.

- Group 2- CCA (iCCA or eCCA) with FGFR2 gene fusions that are chemotherapy naive or
intolerant to first line chemotherapy (i.e., on chemotherapy regimen ≤ 1 cycle).

- Group 3 - CCA (iCCA or eCCA) with FGFR2 gene fusions treated with prior FGFR inhibitors.

- Group 4 - CCA (iCCA or eCCA) with other FGFR2 abnormalities, ie, gene mutations,
rearrangements or amplifications.

- Group 5 - GBM or grade III glioma (i.e, anaplastic astrocytoma or anaplastic
oliogodendroglioma) with FGFR gene fusions or activating mutations

- Group 6 - Advanced urothelial carcinoma with FGFR3 fusions or FGFR3 activating
mutations.

- Group 7: Basket of tumor types with tumors harboring FGFR2 amplification (≥10 copies).

- Group 8 - Basket of tumor types (except CCA, brain tumors and advanced urothelial
carcinomas) with tumors harboring FGFR gene fusions or activating mutations.

Phase 2:

Approximately 100 iCCA patients with confirmed FGFR2 gene fusions will be treated. Patients
will be centrally screened for FGFR2 gene fusions. This is a Single arm study with the
primary endpoint of ORR.

Inclusion Criteria:

Has histologically or cytologically confirmed, locally advanced, metastatic cancer meeting
the following criteria:

Phase 1 Expansion

1. Patient has failed all standard therapies or standard therapy does not exist or is not
tolerated.

2. Patient has specific FGF/FGFR aberrations

- Intrahepatic or extrahepatic cholangiocarcinoma with FGFR2 gene fusions or other
FGFR2 abnormalities, i.e., gene mutations (see Appendix A), rearrangements or
amplifications

- Glioblastoma or grade III glioma (i.e., anaplastic astrocytoma or anaplastic
oligodendroglioma) with FGFR gene fusions or activating mutations.

- Advanced urothelial carcinoma with FGFR3 fusions or FGFR3 activating mutations

- All other tumor types harboring FGF9, FGF19 or FGFR2 amplifications (≥ 10
copies), FGFR gene fusions, or FGFR activating mutations

Phase 2

1. Patient has histologically or cytologically confirmed, locally advanced, metastatic,
unresectable iCCA harboring FGFR2 gene fusions based on results from a NGS assay by
the Sponsor's designated central laboratory

2. Patient has been treated with and failed at least one prior systemic gemcitabine and
platinum-based chemotherapy for the advanced disease

3. Must have documentation of radiographic progression of disease on prior systemic
therapy

4. Patient has measurable disease as defined by Response Evaluation Criteria in Solid
Tumors (RECIST) guidelines (version 1.1, 2009) for advanced solid tumors or RANO
criteria (2010) for brain tumors.

5. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

6. Adequate organ function

Exclusion Criteria:

A patient will be excluded from this study if any of the following criteria are met:

1. History and/or current evidence of non-tumor related alteration of calcium-phosphorus
homeostasis.

2. History and/or current evidence of clinically significant ectopic
mineralization/calcification.

3. History and/or current evidence of clinically significant retinal disorder confirmed
by retinal examination.

4. A serious illness or medical condition(s)
We found this trial at
28
sites
Newnan, Georgia 30265
Phone: 770-400-7191
?
mi
from
Newnan, GA
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
Principal Investigator: Lecia Sequist, MD, MPH
Phone: 617-643-0815
?
mi
from
Boston, MA
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
(716) 845-2300
Phone: 609-250-7208
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
Albuquerque, New Mexico 87109
Phone: 505-272-4946
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Boston, Massachusetts 02215
Phone: 617-667-2100
?
mi
from
Boston, MA
Click here to add this to my saved trials
Boston, Massachusetts 02215
Phone: 617-632-5960
?
mi
from
Boston, MA
Click here to add this to my saved trials
Dallas, Texas 75251
Phone: 972-566-3000
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Detroit, Michigan 48201
Phone: 313-576-8411
?
mi
from
Detroit, MI
Click here to add this to my saved trials
1500 East Duarte Road
Duarte, California 91010
626-256-HOPE (4673)
Phone: 626-471-9200
City of Hope National Medical Center City of Hope is dedicated to making a difference...
?
mi
from
Duarte, CA
Click here to add this to my saved trials
Gilbert, Arizona 85234
Phone: 480-256-5423
?
mi
from
Gilbert, AZ
Click here to add this to my saved trials
900 West Faris Road
Greenville, South Carolina 29605
Principal Investigator: Ki Chung, MD
Phone: 864-455-3600
?
mi
from
Greenville, SC
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Funda Meric-Bernstam, MD
Phone: 713-792-3737
?
mi
from
Houston, TX
Click here to add this to my saved trials
Jacksonville, Florida 32216
Phone: 904-953-3814
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Madison, Wisconsin 53792
Phone: 608-262-5223
?
mi
from
Madison, WI
Click here to add this to my saved trials
300 Grattan Street
Melbourne, 3050
Phone: 609-250-7208
?
mi
from
Melbourne,
Click here to add this to my saved trials
8701 W Watertown Plank Rd
Milwaukee, Wisconsin
(414) 955-8296
Phone: 866-680-0505
Medical College of Wisconsin The Medical College (MCW) of Wisconsin is a major national research...
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
601 E Rollins St
Orlando, Florida 32803
(407) 303-5600
Phone: 609-250-7208
Florida Hospital Florida Hospital is one of the country
?
mi
from
Orlando, FL
Click here to add this to my saved trials
3451 Walnut St
Philadelphia, Pennsylvania 19104
1 (215) 898-5000
Phone: 609-250-7208
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19124
Phone: 215-537-6438
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19107
Phone: 215-955-6407
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
200 Lothrop St
Pittsburgh, Pennsylvania 15213
Phone: 412-623-5396
University of Pittsburgh Medical Center UPMC is one of the leading nonprofit health systems in...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
221 1st Avenue Southwest
Rochester, Minnesota 55902
Phone: 507-538-3365
?
mi
from
Rochester, MN
Click here to add this to my saved trials
1450 3rd Street
San Francisco, California 94158
Phone: 415-502-4174
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
Scottsdale, Arizona 85259
Phone: 480-342-4800
?
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Seattle, Washington 98111
Phone: 206-341-8945
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Spartanburg, South Carolina 29303
Phone: 864-560-7579
?
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Westwood, Kansas 66205
Phone: 913-945-8871
?
mi
from
Westwood, KS
Click here to add this to my saved trials
Zion, Illinois 60099
Phone: 847-872-4019
?
mi
from
Zion, IL
Click here to add this to my saved trials